Abstracts tagged "Vasculitis"

Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting
Efficacy of Leflunomide for Treatment of Vasculitis
NOURA MUSTAPHA ¹, Lillian Barra ², Simon Carette ³, David Cuthbertson ⁴, Nader A. Khalidi ⁵, Curry L. Koening ⁶, Carol Langford ⁷, Carol McAlear ⁸, Nataliya Milman ⁹, Larry Moreland ¹⁰, Paul Monach ¹¹, Philip Seo ¹², Ulrich Specks ¹³, Antoine Sreih ¹⁴, Steven Ytterberg ¹³, Peter Merkel ¹⁴, Christian Pagnoux¹⁵, CanVasc Canadian Vasculitis Research Network ¹⁶ and VCRC Vasculitis Clinical Research Consortium ⁸, ¹Hopital Notre Dame, Montreal, QC, Canada, ²St Joseph's health care, London, Canada, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Utah Hospital, Salt Lake City, UT, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Division of Rheumatology, Philadelphia, ⁹Arthritis Centre at the Ottawa Hospital, Riverside Campus, Ottawa, Canada, ¹⁰University of Pittsburgh, PITTSBURGH, PA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Johns Hopkins Medicine, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA, ¹⁵Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁶Mount Sinai Hospital, Vasculitis clinic, toronto, ON, Canada
Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…
Abstract Number: 2638 • 2019 ACR/ARP Annual Meeting
The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis
Irena Doubelt¹, David Cuthbertson ², Gunnar Tomasson ³, Simon Carette ¹, Nader A. Khalidi ⁴, Curry L. Koening ⁵, Carol Langford ⁶, Carol A. McAlear ⁷, Larry W. Moreland ⁸, Paul Monach ⁹, Philip Seo ¹⁰, Ulrich Specks ¹¹, Antoine Sreih ¹², Kalen Young ¹³, Steven Ytterberg ¹¹, Peter A. Merkel ¹⁴, Christian Pagnoux ¹ and VCRC Vasculitis Clinical Research Consortium ¹⁵, ¹Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²University of South Florida, Tampa, FL, ³Faculty of Medicine, University of Iceland and Landpitali University Hospital, Reykjavik, Iceland, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah Hospital, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Johns Hopkins Medicine, Baltimore, MD, ¹¹Mayo Clinic College of Medicine, Rochester, MN, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Vasculitis Foundation, Kansas City, MO, ¹⁴Univeristy of Pennsylvania, Philadelphia, PA, ¹⁵University of Pennsylvania, Division of Rheumatology, philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma and other manifestations of vasculitis, some of which can be life-threatening, cause major organ damage,…
Abstract Number: 966 • 2019 ACR/ARP Annual Meeting
Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients
Laura van Dam¹, Jelle Oskam ², Sylvia Kamerling ², Eline Arends ², Edwin Bredewold ², Magda Berkowska ², Jacques van Dongen ², Ton Rabelink ², Cees van Kooten ² and Onno Teng ², ¹LUMC, Leiden, Zuid-Holland, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…
Abstract Number: 1712 • 2019 ACR/ARP Annual Meeting
Head and Neck Involvement of IgA Vasculitis: A Case-Control Study
Michel Villatoro-Villar¹, David Wetter ¹, Cynthia Crowson ², Kenneth Warrington ¹ and Matthew Koster ¹, ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic Rochester, Rochester
Background/Purpose: IgA vasculitis (IgAV) is an immune-complex mediated, small-vessel vasculitis which predominantly involves the skin on the lower extremities. Head and neck involvement is rarely…
Abstract Number: 2641 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Jason Springer¹, Tanaz Kermani ², Antoine Sreih ³, Dianne Shaw ⁴, Kalen Young ⁵, Cristina Burroughs ⁶ and Peter Merkel ³, ¹Kansas University Medical Center, Kansas, MO, ²University of California Los Angeles, Los Angeles, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Vasculitis Foundation, North Carolina, ⁵Vasculitis Foundation, Kansas City, MO, ⁶University of South Florida, Tampa, FL
Background/Purpose: To provide a feasible and sustainable platform for conducting patient-centered research in vasculitis, a prospective, international, internet-based registry of patients with vasculitis has been…
Abstract Number: 970 • 2019 ACR/ARP Annual Meeting
New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction
Emilie Chan¹, Susan Hartzell ², Lisa Anderson ², Chiara Cantarelli ², Chiara Guglielmo ², Ioannis Tassiulas ³, Sofia Andrighetto ², Andrea Angeletti ⁴, Joaquin Manrique Escola ⁵ and Paolo Cravedi ², ¹Mount Sinai Hospital, New York, NY, ²Mount Sinai Hospital, New York, ³Icahn School of Medicine, New York, ⁴Sant'Orsola-Malpighi Hospital, Bologna, Italy, ⁵Complejo Hospital de Navarra, Pamplona, Spain
Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by the production of auto-antibodies and can be treated with rituximab, a B cell-depleting agent. Despite this, limited data…
Abstract Number: 1713 • 2019 ACR/ARP Annual Meeting
Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
CAMILLE RASMUSSEN¹, MYLENE TISSEYRE ², JULIE GARON-CZMIL ², MARINA ATZENHOFFER ³, Loïc Guillevin ⁴, LAURENT CHOUCHANA ² and Benjamin Terrier ⁴, ¹Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, PARIS, PARIS, France, ²PHARMACOVIGILANCE, COCHIN HOSPITAL, PARIS, PARIS, France, ³PHARMACOVIGILANCE CENTER LYON, FRANCE, LYON, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: IgA vasculitis (IgAV) is an immune complex small-vessel vasculitis, with IgA1-dominant immune deposits. Drug-induced IgAV were rarely reported in the literature, but no systematic…
Abstract Number: 2689 • 2019 ACR/ARP Annual Meeting
GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
Maria C. Cid¹, Rohan Gandhi ², Marc Corbera-Bellalta ³, Nekane Terrades-Garcia ³, Sujatha Muralidharan ⁴ and John F Paolini ⁵, ¹Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ²Kiniksa Pharmaceuticals Corp., san diego, CA, ³Vasculitis Research Unit, Department of Autoimmune Diseases, University of Barcelona, Barcelona, Spain, ⁴Kiniksa Pharmaceuticals Corp., lexington, MA, ⁵Kiniksa Pharmaceuticals Corp, lexington, MA
Background/Purpose: Giant Cell Arteritis (GCA) is a type of large vessel vasculitis that can cause blindness and aortic aneurysms. A significant unmet medical need remains…
Abstract Number: 821 • 2018 ACR/ARHP Annual Meeting
Comparison of Aortitis Vs Non-Inflammatory Aortic Aneurysms Among Patients Who Undergo Open Aortic Aneurysm Repair
Laarni Quimson¹, Bryan Rea² and Rennie L. Rhee³, ¹Internal Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Comparison of Aortitis vs Non-Inflammatory Aortic Aneurysms Among Patients Who Undergo Open Aortic Aneurysm RepairBackground/Purpose: Distinguishing aortitis-induced aneurysms from more common non-inflammatory aortic aneurysms is…
Abstract Number: 828 • 2018 ACR/ARHP Annual Meeting
Medium and Small-Sized Vessel Involvement in Hypereosinophilic Syndrome
Julien Rohmer¹, Matthieu Groh², Maxime Samson³, Jonathan London⁴, Marie JACHIET⁵, Diane Rouzaud⁶, Antoinette Perlat⁷, Romain Paule⁸, Felipe SUAREZ⁹, Jean-Emmanuel Kahn¹⁰, Loïc Guillevin¹¹ and Benjamin Terrier¹², ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Internal medicine, France, Paris, France, ²Internal Medicine, Foch, Suresnes, France, ³Dijon University Hospital, Dijon, France, ⁴Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁵Dermatology department, St Louis Hospital, Paris, France, ⁶Université Paris-Diderot, Paris, France, ⁷Internal medicine, CHU de Rennes, Rennes, France, ⁸Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁹Hematology Department, Necker Hospital, Paris, France, ¹⁰Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, ¹¹Medecine Interne, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Primary systemic vasculitis, especially eosinophilic granulomatosis with polyangiitis and polyarteritis nodosa, can be associated with blood and tissue eosinophilia. Conversely, eosinophilia in the context…
Abstract Number: 833 • 2018 ACR/ARHP Annual Meeting
11 Patients with Relapsing Polychondritis Presenting with Severe Airways Disease in One Centre in UK
Shirish Dubey¹, Grace Pink², Asad Ali², Nicholas Hart³, Patrick Murphy⁴, Joanne Shakespeare⁵, Colin Gelder⁶, Chris Taylor² and David D'Cruz⁷, ¹Rheumatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ²Respiratory medicine, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ³Respiratory medicine, St Thomas' Hospital, London, United Kingdom, ⁴Lane Fox Respiratory Unit, St Thomas' Hospital, London, United Kingdom, ⁵Respiratory physiology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ⁶University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ⁷Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Relapsing polychondritis (RP) is a multi-system disease characterised by episodes of progressive inflammation and subsequent degeneration of cartilage and connective tissue throughout the body.…
Abstract Number: 1317 • 2018 ACR/ARHP Annual Meeting
Tracheomalacia in Coventry in UK
Grace Pink¹, Shirish Dubey², Asad Ali¹, Joanna Shakespeare³, Chris Taylor¹ and Colin Gelder⁴, ¹Respiratory medicine, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ²Rheumatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ³Respiratory Physiology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ⁴University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
Background/Purpose: Tracheomalacia (TM) is pathological diffuse or segmental narrowing of the tracheal lumen, caused by softening of the supporting cartilage and reduction in stiffness of…
Abstract Number: 3079 • 2016 ACR/ARHP Annual Meeting
The Characteristic Features of the Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
Abdulsamet Erden¹, Ezgi Deniz Batu², Ekim Z. Taskiran³, Hafize Emine Sonmez², Alper Sari¹, Berkan Armagan¹, Levent Kilic¹, Zehra Serap Arıcı⁴, Yelda Bilginer⁵, Ali Akdogan¹, Omer Karadag¹, Umut Kalyoncu¹ and Seza Ozen^6,7, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Medical Genetics, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ⁴Departments of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Departments of Pediatric Nephrology and Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disease resulting from a loss-of-function mutation in Cat Eye Syndrome Chromosome Region Candidate…
Abstract Number: 1339 • 2015 ACR/ARHP Annual Meeting
Granulomatosis with Polyangiitis or Post Pulmonary Tuberculosis: Can CT Chest Help in Differentiating in a Tuberculosis Endemic Area?
Aman Sharma¹, Manphool Singhal², Mitali Sen³, Manish Rathi⁴, Varun Dhir¹, Kusum Sharma⁵, Ranjana Minz⁶, Surjit Singh³, Pradeep Bambery⁷ and Niranjan Khandelwal², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Radiodiagnosis, PGIMER,, Chandigarh, India, ³Department of Internal Medicine,, PGIMER,, Chandigarh, India, ⁴Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁵Department of Medical Microbiology,, PGIMER,, Chandigarh, India, ⁶Department of Immunopathology,, PGIMER,, Chandigarh, India, ⁷Rheumatology, Bundaberg base hospital, University of Queensland, Bundaberg, Australia
Background/Purpose: The data on the Computed tomography (CT) changes of chest in Granulomatosis with polyangiitis (GPA) is available mostly from low tuberculosis prevalence countries. We…
Abstract Number: 1978 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Large Vessel Vasculitis with Aorta Involvement. Study on 10 Patients Evaluated By Positron Emission Tomoghraphy
Carlotta Nannini¹, Stelvio Sestini², Laura Niccoli³, Emanuele Cassarà⁴, Olga Kaloudi⁵ and Fabrizio Cantini⁶, ¹Rheumatology, Prato Hospital, Prato, Italy, ²Radiology Department, Prato, Italy, ³Prato Hospital, Prato, Italy, ⁴Rheumatology, Hospital of Prato, Prato, Italy, ⁵PRato, Prato Hospital, Prato, Italy, ⁶Prato, Prato, Italy
Background/Purpose: Large vessel vasculitis (LVV) with aorta involvement are often refractory to common immunosuppressive therapy. Due to the pathogenic role of IL-6 in, we prospectively…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].